California is currently home to 5603 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease
Recruiting
This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells (known as CRISPR_SCD001 Drug Product).
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
09/18/2024
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Sickle Cell Disease
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: Local Institution - 001-840-B, Bellflower, California
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Recruiting
The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: Stanford University Medical Center, Stanford, California
Conditions: Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
Neuroblastoma Maintenance Therapy Trial
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: UCSF Benioff Children's Hospital Oakland-, Oakland, California
Conditions: Neuroblastoma
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
Recruiting
A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: Site USA08-0, Newport Beach, California
Conditions: Solid Tumor, Adult
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed or Refractory Grade 1-3a Follicular Lymphoma
Recruiting
This phase II trial tests how well mosunetuzumab and polatuzumab vedotin works in treating patients with grade 1-3a follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B po... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma
Phase 2 Study of EDG-5506 in Children and Adolescents with Duchenne Muscular Dystrophy Previously Treated with Gene Therapy (FOX)
Recruiting
The FOX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics, and biomarkers in children and adolescents with Duchenne muscular dystrophy previously treated with gene therapy including a randomized, double-blind, placebo-controlled Part A, followed by an open-label part B.
Gender:
MALE
Ages:
Between 6 years and 17 years
Trial Updated:
09/17/2024
Locations: UCLA Medical Center, Los Angeles, California
Conditions: Duchenne Muscular Dystrophy
Acetazolamide in Persons with Type 1 Diabetes
Recruiting
This is a dose finding trial where participants will receive escalating doses of acetazolamide, each for a 2-week dosing period followed by a 2-week washout period. The three doses examined will be open-label 62.5mg twice daily, 125mg twice daily, and 250mg twice daily of acetazolamide. A baseline Iohexol GFR (glomerular filtration rate) measurement will be performed prior to the first administration of each acetazolamide dose and then again following each dosing period. Including a screening vi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California
Conditions: Type 1 Diabetes
Evaluation of SINGLE PORT (SP) Robotic Technology in Colorectal Surgery
Recruiting
Currently a multiport robotic surgery platform (Intuitive Xi) is widely available and used for colorectal surgery indications. A Single port platform (Intuitive SP) is FDA approved for Head and Neck and Urology but has not been widely used in colorectal surgery. This study seeks to evaluate the safe and effective use of the SP platform for colorectal surgery indications.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: UC Davis Medical Center, Sacramento, California
Conditions: Colo-rectal Cancer, Rectal Prolapse, Colostomy Stoma, Colorectal Disorders
Brentuximab Vedotin and Nivolumab for the Treatment of Patients with Relapsed/refractory Classical Hodgkin Lymphoma
Recruiting
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune sys... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Relapsed Classic Hodgkin Lymphoma
Abemaciclib and Endocrine Therapy in Older Patients with Breast Cancer.
Recruiting
This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
09/17/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Recruiting
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk... Read More
Gender:
FEMALE
Ages:
Between 35 years and 50 years
Trial Updated:
09/17/2024
Locations: Kaiser Permanente-Deer Valley Medical Center, Antioch, California
Conditions: Ovarian Carcinoma